Clinical Trials Logo

Clinical Trial Summary

This is a single center, diagnostic clinical trial in which the investigators aim to prospectively validate a deep learning model that identifies patients with features suggestive of cardiac amyloidosis, including transthyretin cardiac amyloidosis (ATTR-CA). Cardiac Amyloidosis is an age-related infiltrative cardiomyopathy that causes heart failure and death that is frequently unrecognized and underdiagnosed. The investigators have developed a deep learning model that identifies patients with features of ATTR-CA and other types of cardiac amyloidosis using echocardiographic, ECG, and clinical factors. By applying this model to the population served by NewYork-Presbyterian Hospital, the investigators will identify a list of patients at highest predicted risk for having undiagnosed cardiac amyloidosis. The investigators will then invite these patients for further testing to diagnose cardiac amyloidosis. The rate of cardiac amyloidosis diagnosis of patients in this study will be compared to rate of cardiac amyloidosis diagnosis in historic controls from the following two groups: (1) patients referred for clinical cardiac amyloidosis testing at NewYork-Prebysterian Hospital and (2) patients enrolled in the Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations (SCAN-MP) study.


Clinical Trial Description

Heart failure is a leading cause of death in the United States and throughout the world. One cause of heart failure is transthyretin cardiac amyloidosis (ATTR-CA), in which misfolded proteins deposit into the heart. This condition is often diagnosed very late when patients have severe symptoms. In this study, the investigators are trying to use a computer algorithm to find patients with cardiac amyloidosis that has not been diagnosed or suspected by their doctors. The investigators will look at patients seen at Columbia University Irving Medical Center and use our algorithm to identify 100 patients with a high probability of having cardiac amyloidosis and bring them in to be tested. - ATTR-CA diagnosis: A diagnosis of ATTR-CA will be made according to consensus guidelines by an amyloidosis expert. These criteria include either (1) imaging criteria with requires that a patient's cardiac amyloid scintigraphy single-photon emission computed tomography (SPECT) scan shows myocardial uptake, increase left ventricular (LV) wall thickness by cardiac imaging that is unexplained by loading conditions, and follow-up monoclonal protein testing shows no evidence of clinical amyloid light-chain (AL) amyloidosis or (2) pathologic criteria with a biopsy showing systemic transthyretin deposition. - Cardiac amyloidosis (AL-CA) diagnosis: A clinical diagnosis of AL-CA will be by an amyloidosis expert according to society guidelines. These includes a diagnosis made in one of the following settings: (1) cardiac biopsy showing AL deposition and (2) extra-cardiac biopsy showing AL deposition with typical cardiac features on imaging such as echocardiography or cardiac magnetic resonance imaging. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06469372
Study type Interventional
Source Columbia University
Contact Timothy J. Poterucha, MD
Phone (212) 932-4537
Email tp2558@cumc.columbia.edu
Status Recruiting
Phase N/A
Start date May 28, 2024
Completion date December 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04459169 - Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Recruiting NCT06034405 - Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Recruiting NCT04915235 - Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
Recruiting NCT02966522 - Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis Phase 2
Terminated NCT03333551 - Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy Phase 4
Recruiting NCT04105634 - Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT Early Phase 1
Recruiting NCT05139797 - Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Not yet recruiting NCT05593679 - A Multi-center Cardiac PYP Scan Registry in Taiwan.
Not yet recruiting NCT04146415 - Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera N/A
Not yet recruiting NCT06427304 - Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
Recruiting NCT04856267 - Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
Completed NCT03119558 - PET/MRI Evaluation of Cardiac Amyloid Early Phase 1
Recruiting NCT02798705 - Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Not yet recruiting NCT04387344 - Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
Recruiting NCT06129656 - Cardiac Amyloidosis Registry of University Hospital Leipzig
Terminated NCT01683825 - Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography Phase 4
Withdrawn NCT04363294 - Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot N/A
Not yet recruiting NCT04661800 - Study of Olfactory Disorders in Patients With Cardiac Amyloidosis N/A
Terminated NCT03232632 - Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries. Early Phase 1